Price
No data yet.
Social Signal Score
Analyst Ratings
2 analystsRevenue
$0.00-100.00%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Pardeep Nijhawan
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 17
- Beta
- 1.06
- Country
- CA
- Piotroski score
- 1 / 9 (Weak)
- Altman Z-score
- -5.96
Financials
Revenue
$0.00-100.0%Net Income
$-5.41MEBITDA
$-5.52MFree Cash Flow
$-3.05MEPS (diluted)
$-0.60Shares Outstanding (diluted)
9.01M+3670.0%Operating Expenses
$5.52MCash & Debt
$10.33MRevenue by Segment (annual)
$211.8KQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $0.00 | $-7.19M | $-1.27 |
| 2024 | $0.00 | $-6.17M | $-1.93 |
| 2023 | $0.00 | $-8.37M | $-2.93 |
| 2022 | $0.00 | $-17.55M | $-8.37 |
| 2021 | $0.00 | $-13.34M | $-7.73 |
| 2020 | $328.8K | $-6.36M | $-5.18 |
| 2019 | $410.9K | $-2.72M | $-4.79 |
| 2018 | $211.8K | $-5.04M | $-3.32 |
| 2017 | $228.3K | $-5.03M | $-36.78 |
| 2016 | $1.27M | $-5.03M | $-23.92 |
| 2015 | $758.7K | $-2.84M | $-15.01 |
| 2014 | $372.1K | $-8.44M | $-46.75 |
| 2013 | $545.5K | $-14.89M | $-121.14 |
| 2012 | $286.1K | $-5.20M | $-49.86 |
Valuation
EDSAhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
130+160.00%Social Signal Score
Mentions (3)
- Newsglobenewswire.com·47d ago·Negative
Edesa Biotech Announces Pricing of $25.0 Million Public Offering TORONTO, Aug. 19, 2026 (GLOBE NEWSWIRE) -- Edesa Biotech, Inc. (Nasdaq: EDSA) (the “Company” or “Edesa”), a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory diseases, today announced the pricing of an underwritten public offering consisting of (i) 3,870,500 common shares and accompanying common share warrants to purchase an aggregate of 3,870,500 common shares and (ii…
View source ↗ - Newsglobenewswire.com·47d ago·Negative
Edesa Biotech Announces Proposed Public Offering TORONTO, Aug. 19, 2026 (GLOBE NEWSWIRE) -- Edesa Biotech, Inc. (Nasdaq: EDSA) (the “Company” or “Edesa”), a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory diseases, today announced that it has commenced an underwritten public offering of its common shares (or pre-funded warrants to purchase common shares in lieu thereof) and accompanying common share warrants to purchase common sha…
View source ↗ - Newsglobenewswire.com·53d ago·Neutral
Edesa Biotech Reports Fiscal 3rd Quarter 2026 Results TORONTO, Aug. 13, 2026 (GLOBE NEWSWIRE) -- Edesa Biotech, Inc. (Nasdaq:EDSA), a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory diseases, today reported financial results for the three and nine months ended June 30, 2026 and provided an update on its business.
View source ↗
Earnings
Fri, Dec 11(in 2 months)
Consensus estimate $-0.58 per share
Typical surprise -18.5% (median, so one quarter with a near-zero estimate can't distort it)
- Thu, Aug 13$-0.60 vs $-0.43miss
- Thu, May 14$-0.49 vs $-0.24miss
- Fri, Feb 13$-0.28 vs $-0.28beat
- Fri, Dec 12$-0.32 vs $-0.27miss
- Fri, Aug 8$-0.25 vs $-0.26beat
- Wed, May 14$-0.30 vs $-0.30beat
Estimates and results for EDSA via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by EDSA officers and directors.
- Bought
- $320k
- Sold
- $788k
13 trades
4 trades
- Nijhawan Pardeepbought
- Nijhawan Pardeepbought
- Nijhawan Pardeepbought
- Nijhawan Pardeepbought
- Nijhawan Pardeepbought
- Nijhawan Pardeepboughtdirector, 10 percent owner, officer: Chief Executive Officer·30,000 @ $2.22·$67k·Feb 27, 2026·filing
- Brooks Michael Jbought
- Nijhawan Pardeepboughtdirector, 10 percent owner, officer: Chief Executive Officer·20,571 @ $1.58·$32k·Feb 26, 2026·filing
83 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in EDSA.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.